|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A rare case of hyaline-type Castleman disease in the liver显示文摘Castleman disease often develops in the neck, mediastinum and pulmonary hilum. Its onset in the peritoneal cavity is very rare. The patient, a woman in her 70s, was referred to our department for a detailed examination of an abdominal mass. On abdominal ultrasonography, computed tomography scan, magnetic resonance imaging and positron emission tomography, a mass approximately 15 mm in diameter was noted in the hepatic S6. We attempted radical treatment and conducted a laparoscope-assisted right lobectomy. On the basis of histopathological findings, the patient was diagnosed as having hyaline type Castleman disease in the liver, a very rare condition. | Hisaaki Miyoshi Shima Mimura Takako Nomura Joji Tani Asahiro Morishita Hideki Kobara Hirohito Mori Hirohito Yoneyama Akihiro Deguchi Takashi Himoto Naoki Yamamoto Keiichi Okano Yasuyuki Suzuki Tsutomu Masaki | 2013 | World Journal of Hepatology2013，5，7： | 14 |
| 2 | Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions显示文摘AIM To investigate daclatasvir(DCV) and asunaprevir(ASV) efficacy in hepatitis C(HCV) patients, with respect to resistance-associated substitutions(RASs).METHODS A total of 392 HCV-infected patients from multiple centers were included in this study. We evaluated their clinical courses and sustained virologic responses(SVR) according to pretreatment factors(gender, age, history of interferon-based regimens, platelet counts, level of viremia, pretreatment NA5A:L31, and Y93 substitutions). We also analyzed the pretreatment and post-treatment major RASs of NS3:D168, NS5A:L31 and Y93 substitutions using a direct-sequencing method in 17 patients who were unable to achieve SVR at 12 wk after treatment completion(SVR12).RESULTS The overall SVR12 rate was 88.3%. Thirty-one patients discontinued treatment before 24 wk because of adverse events, 23 of whom achieved SVR12. There were no significant differences in SVR12 rates with respect to gender, age, history of interferon-based regimens, and platelet counts. The SVR12 rate in patients with viral loads of ≥ 6.0 log IU/m L was significantly lower than those with viral loads of < 6.0 log IU/m L(P < 0.001). The SVR12 rate in patients with Y93 substitution-positive was significantly lower than those with Y93 substitution-negative(P < 0.001). The L31 substitution-positive group showed a lower SVR12 rate than the L31 substitution-negative group, but the difference was not statistically significant. Seventeen patients who did not achieve SVR12 and had available pretreatment and post-treatment sera had additional RASs in NS3:D168, NS5:L31, and Y93 substitution at treatment failure.CONCLUSION Combination of DCV and ASV is associated with a high SVR rate. Baseline RASs should be thoroughly assessed to avoid additional RASs after treatment failure. | Hideki Fujii Atsushi Umemura Taichiro Nishikawa Kanji Yamaguchi Michihisa Moriguchi Hideki Nakamura Kohichiroh Yasui Masahito Minami Saiyu Tanaka Hiroki Ishikawa Hiroyuki Kimura Shiro Takami Yasuyuki Nagao Toshihide Shima Yoshito Itoh | 2017 | World Journal of Hepatology2017，9，25： | 3 |
| 3 | Effect of the anti-diabetic drug metformin in hepatocellular carcinomain vitro and in vivo显示文摘 | Hisaaki Miyoshi Kiyohito Kato Hisakazu Iwama Emiko Maeda Teppei Sakamoto Koji Fujita Yuka Toyota Joji Tani Takako Nomura Shima Mimura Mitsuyoshi Kobayashi Asahiro Morishita Hideki Kobara Hirohito Mori Hirohito Yoneyama Akihiro Deguchi Takashi Himoto Kazut | 2014 | International Journal of Oncology2014，，1： | 3 |
| 4 | Expression of angiogenic factors in hepatocarcinogenesis: Identificationby antibody arrays显示文摘 | Takako Nomura Asahiro Morishita Gong Jian Shima Mimura Kiyohito Kato Kei Nomura Joji Tani Hisaaki Miyoshi Hirohito Yoneyama Teppei Sakamoto Koji Fujita Emiko Maeda Hideki Kobara Hirohito Mori Hisakazu Iwama Tsutomu Masaki | 2013 | Oncology Reports2013，，5： | 1 |
| 5 | Antitumor effect of metformin in esophageal cancer: In vitro study显示文摘 | Mitsuyoshi Kobayashi Kiyohito Kato Hisakazu Iwama Shintaro Fujihara Noriko Nishiyama Shima Mimura Yuka Toyota Takako Nomura Kei Nomura Joji Tani Hisaaki Miyoshi Hideki Kobara Hirohito Mori Koji Murao Tsutomu Masaki | 2013 | International Journal of Oncology2013，，2： | 1 |
| 6 | Glial - de- rived growth factor signaling pathway in infantile hypertrophic pyloric stenosis显示文摘 | Nino Guarino Hideki Shima Takaharu Oue Prem Puri | 2000 | J Pediatr Surg2000，35，6： | 1 |
| 7 | Initial experience with non-breath-hold magnetic resonance cholangiopancreatography: A new noninvasive technique for the diagnosis of choledochal cyst in children显示文摘 | Atsuyuki Yamataka Ryohei Kuwatsuru Hideki Shima Hiroyuki Kobayashi Geoffrey Lane Osamu Segawa Hitoshi Katayama Takeshi Miyano | 1997 | Journal of Pediatric Surgery1997，，11： | 1 |
| 8 | Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching显示文摘AIM: To compare efficacy of telaprevir(TVR) and simeprevir(SMV) combined with pegylated interferon(PEG-IFN) and ribavirin(RBV) while treating chronic hepatitis C(CHC). METHODS: In all, 306 CHC patients were included in this study. There were 159 patients in the TVR combination therapy group and 147 patients in the SMV combination therapy group. To evaluate pretreatment factors contributing to sustained virological response at 12 wk(SVR12), univariate and multivariate analyses were performed in TVR and SMV groups. To adjust for patient background between TVR and SMV groups, propensity score matching was performed. Virological response during treatment and SVR12 were evaluated.RESULTS: Overall rates of SVR12 [undetectable serum hepatitis C virus(HCV) RNA levels] were 79.2% and 69.4% in TVR and SMV groups, respectively. Patients in the SMV group were older, had higher serum HCV RNA levels, lower hemoglobin, higher prevalence of unfavorable interleukin-28B(IL28B) genotype(rs8099917), and poorer response to previous PEG-IFN and RBV treatment. Propensity score matching was performed to adjust for backgrounds(n = 104) and demonstrated SVR12 rates of 74.0% and 73.1% in the TVR and SMV groups, respectively. In the TVR group, discontinuation rates were higher because of adverse events; however, breakthrough and nonresponse was more frequent in the in SMV group. Multivariate analysis revealed IL28 B genotype(rs8099917) as the only independent predictive factor of SVR12 in both groups.CONCLUSION: SVR12 rates were almost identical following propensity score matching. | Hideki Fujii Takeshi Nishimura Atsushi Umemura Taichiro Nishikawa Kanji Yamaguchi Michihisa Moriguchi Yoshio Sumida Hironori Mitsuyoshi Chihiro Yokomizo Saiyu Tanaka Hiroki Ishikawa Kenichi Nishioji Hiroyuki Kimura Shiro Takami Yasuyuki Nagao Takayuki Takeuchi Toshihide Shima Yoshihiko Sawa Masahito Minami Kohichiroh Yasui Yoshito Itoh | 2015 | World Journal of Hepatology2015，7，28： | 1 |
| 9 | 层析成像技术在工程场地勘察中的应用显示文摘引言地质层析成像是一种由地球物理技术测得的数据来重构地下介质物性剖面的方法。对不同物理现象和重构物性剖面有不同的层析图像。本文作者发展了下列三种层析成像技术,并将其应用于工程中大坝等场地地基的勘察。地震层析成像地震波速度分布的重构雷达层析成像电磁波速度分布的重构电阻率层析成像电阻率分布的重构使用这三种层析成像技术。 | Hideki Saito Hiromasa Shima 韦宝珠 | 1991 | 勘察科学技术1991，，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员